Table 4.
Clinical study on M2-like TAMs treatment strategies to overcome tumor drug resistance.
| Intervention | Statustumor type | Status | gov identifier | Refs | |
|---|---|---|---|---|---|
| Reduce M2-like TAMs in TME | |||||
| JAK inhibitor | Ruxolitinib | Relapsed/refractory multiple myeloma patients | Completed | NCT03311854 | 155 |
| CSF-1R inhibitor | Pexidartinib | Unresectable sarcoma and MPNST | Completed | NCT02584647 | 151 |
| Emactuzumab | Advanced/metastatic solid tumors | Completed | NCT01494688 | 152 | |
| AMG 820 | Advanced solid tumors | Completed | NCT02713529 | 196 | |
| Cabiralizumab | Melanoma, RCC, or NSCLC resistant to anti-PD-1/PD-L1 | Completed | NCT03502330 | 197 | |
| CCR5 inhibitor | Maraviroc | refractory MMRp/MSS metastatic CRC | Ongoing | NCT03274804 | 152 |
| TAM inhibitor | Sitravatinib | Advanced clear cell renal cell carcinoma | Completed | NCT03015740 | 198 |
| VEGFR2 inhibitor | Anlotinib | Advanced NSCLC | Completed | NCT03628521 | 199 |
| Repolarize M2-like to M1-like TAMs | |||||
| CSF-1R inhibitor | Pexidartinib | Advanced, treatment refractory solid tumors | Completed | NCT01525602 | 175 |
| ARRY-382 | Advanced solid tumors | Completed | NCT02880371 | 200 | |
| BLZ945 | Advanced solid tumors | Ongoing | NCT02829723 | 175 | |
| LY3022855 | Advanced solid tumors | Completed | NCT02718911 | 201 | |
| CSF-1 inhibitor | Lacnotuzumab | Advanced triple-negative breast cancer | Not yet recruiting | NCT02435680 | 202 |
| PD-0360324 | Locally advanced or metastatic solid tumors | Ongoing | NCT02554812 | 175 | |
| BRD4 inhibitor | AZD5153 | relapsed/refractory solid tumors or lymphoma | Completed | NCT03205176 | 203 |
| CD47-SIRPα inhibitor | Evorpacept | HNSCC | Completed | NCT03013218 | 178 |
| CD40 agonist | APX005M | Melanoma, NSCLC, or RCC | Completed | NCT03502330 | 197 |
| SEA-CD40 | Advanced solid tumors and lymphomas | Completed | NCT02376699. | 181 | |
| PI3Kγ inhibitor | IPI-549 | Advanced solid tumors | Completed | NCT02637531 | 204 |
| Src inhibitor | Dasatinib | NSCLC | Ongoing | NCT00826449 | 205 |
| HDAC inhibitor | Tucidinostat | intermediate- and high-risk early-stage ENKTCL | Completed | NCT04511351 | 206 |
| STAT 3 inhibitors | Danvatirsen | Advanced solid tumors | Completed | NCT03394144 | 207 |
| TGFβ inhibitor | Galunisertib | Unresectable pancreatic cancer | Completed | NCT02734160 | 208 |
| TLR agonist | Vidutolimod | Metastatic melanoma | Completed | NCT03084640 | 209 |